Dihydropyrimidinase deficiency: Phenotype, genotype and structural consequences in 17 patients  by van Kuilenburg, André B.P. et al.
Biochimica et Biophysica Acta 1802 (2010) 639–648
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isDihydropyrimidinase deﬁciency: Phenotype, genotype and structural consequences
in 17 patients
André B.P. van Kuilenburg a,⁎, Doreen Dobritzsch b, Judith Meijer a, Rutger Meinsma a,
Jean-François Benoist c, Birgit Assmann d, Susanne Schubert e, Georg F. Hoffmann e, Marinus Duran a,
Maaike C. de Vries f, Gerd Kurlemann g, François J.M. Eyskens h, Lawrence Greed i, Jörn Oliver Sass j,
K. Otfried Schwab j, Adrian C. Sewell k, John Walter l, Andreas Hahn m, Lida Zoetekouw a, Antonia Ribes n,
Suzanne Lind o, Raoul C.M. Hennekam p
a Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry, Academic Medical Center, Emma Children's Hospital, 1105 AZ Amsterdam, the Netherlands
b Department of Medical Biochemistry and Biophysics (MBB), Karolinska Institutet, S-17177 Stockholm, Sweden
c Service de Biochimie Hormonologie, Hôpital Robert Debré, 75935 Paris Cedex 19, France
d Department of General Pediatrics, University Children's Hospital, 40225 Düsseldorf, Germany
e Department of Pediatrics, University Children's Hospital Heidelberg, 69120 Heidelberg, Germany
f Department of Metabolic and Endocrine Disorders, Radboud University Nijmegen Medical Center, 6500 HB Nijmegen, the Netherlands
g Klinik und Poliklinik für Kinderheilkunde, Universitätsklinikum Münster 48149 Münster, Germany
h Center for Metabolic Disorders, CEMA Antwerp, 2020 Antwerp, Belgium
i Department of Clinical Biochemistry, Princess Margaret Hospital for Children, Perth, Western Australia
j Department of Pediatrics, University Hospital Freiburg, 79106 Freiburg, Germany
k Department of Pediatrics, University Children's Hospital, 60590 Frankfurt am Main, Germany
l Willink Biochemical Genetics Unit, Royal Manchester Children's Hospital Manchester, Manchester M27 4HA, UK
m Department of Neuropediatrics, Justus-Liebig-University, 35392 Giessen, Germany
n Institut de Bioquímica Clínica, Servei de Bioquimica i Genètica Molecular, and CIBERER, Hospital Clínic, 08028 Barcelona, Spain
o Department of Clinical Chemistry, Karolinska Institutet, S-14186 Stockholm, Sweden
p Department of Pediatrics, Academic Medical Center, Emma Children's Hospital, 1105 AZ Amsterdam, the Netherlands⁎ Corresponding author. Academic Medical Center,
Diseases F0-224, Meibergdreef 9, 1105 AZ Amsterdam,
5665958; fax: +31 20 6962596.
E-mail address: a.b.vanKuilenburg@amc.uva.nl (A.B.
0925-4439/$ – see front matter © 2010 Elsevier B.V. A
doi:10.1016/j.bbadis.2010.03.013a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 February 2010
Received in revised form 9 March 2010
Accepted 26 March 2010
Available online 1 April 2010
Keywords:
Dihydropyrimidinase
DPYS
Neurological and gastrointestinal
abnormalities
Crystal structure
Functional and structural protein analysisDihydropyrimidinase (DHP) is the second enzyme of the pyrimidine degradation pathway and catalyses the
ring opening of 5,6-dihydrouracil and 5,6-dihydrothymine. To date, only 11 individuals have been reported
suffering from a complete DHP deﬁciency. Here, we report on the clinical, biochemical and molecular
ﬁndings of 17 newly identiﬁed DHP deﬁcient patients as well as the analysis of the mutations in a three-
dimensional framework. Patients presented mainly with neurological and gastrointestinal abnormalities and
markedly elevated levels of 5,6-dihydrouracil and 5,6-dihydrothymine in plasma, cerebrospinal ﬂuid and
urine. Analysis of DPYS, encoding DHP, showed nine missense mutations, two nonsense mutations, two
deletions and one splice-site mutation. Seventy-one percent of the mutations were located at exons 5–8,
representing 41% of the coding sequence. Heterologous expression of 11 mutant enzymes in Escherichia coli
showed that all but two missense mutations yielded mutant DHP proteins without signiﬁcant activity. Only
DHP enzymes containing the mutations p.R302Q and p.T343A possessed a residual activity of 3.9% and 49%,
respectively. The crystal structure of human DHP indicated that the point mutations p.R490C, p.R302Q and p.
V364M affect the oligomerization of the enzyme. In contrast, p.M70T, p.D81G, p.L337P and p.T343A affect
regions near the di-zinc centre and the substrate binding site. The p.S379R and p.L7V mutations were likely
to cause structural destabilization and protein misfolding. Four mutations were identiﬁed in multiple
unrelated DHP patients, indicating that DHP deﬁciency may be more common than anticipated.Laboratory Genetic Metabolic
the Netherlands. Tel.: +31 20
P. van Kuilenburg).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Pyrimidine nucleotides are essential for a vast number of biological
processes such as synthesis of RNA, DNA, phospholipids, glycogen and
sialylation and glycosylation of proteins [1]. In addition, altered
homeostasis of pyrimidines and their degradation products might
impair neurological function [2–4]. In humans, the pyrimidine bases
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β-alanine and β-aminoisobutyric acid, respectively (Fig. 1). Dihydro-
pyrimidine dehydrogenase (DPD, EC 1.3.1.2) is the initial and rate-
limiting enzyme, catalysing reduction of uracil and thymine to 5,6-
dihydrouracil and 5,6-dihydrothymine, respectively. Subsequently,
dihydropyrimidinase (DHP, EC 3.5.2.2) catalysis the hydrolytic ring
opening of the dihydropyrimidines. Finally, the resulting N-carbamyl-
β-alanine and N-carbamyl-β-aminoisobutyric acid are converted in
the third step to β-alanine and β-aminoisobutyric acid, ammonia and
CO2 by β-ureidopropionase (EC 3.5.1.6).
The enzymes of the pyrimidine degradation pathway are also
involved in degradation of the antineoplastic agent 5-ﬂuorouracil (5FU)
[5]. DPD deﬁcient patients have an increased risk of developing severe
toxicity after 5FU administration [5,6]. Similarly, patients with a DHP
deﬁciency have developed severe 5FU-associated toxicity [7–10].
DHP has been puriﬁed and characterised in eukaryotic species and
the DHP crystal structures from the yeast Saccharomyces kluyveri
(SkDHP), the slime mold Dictyostelium discoideum (DdDHP) and
human DHP have recently been determined [11–15]. These studies
revealed a high structural resemblance between eukaryotic DHP
proteins and those of hydantoinases, the bacterial counterparts of
DHP as well the DHP-like non-catalytic proteins involved in neuronal
development [16–22].
The gene encoding DHP, DPYS, maps to chromosome 8q22 and
consists of 10 exons spanning N80 kb of genomic DNA [23]. The cDNA
coding for human DHP contains an open reading frame of 1560
nucleotides, corresponding to a protein of 519 amino acids with a
calculated molecular weight of 56,629 Da [23].Fig. 1. Catabolic pathway of the pyrimidine bases uracil and thymine.DHP deﬁciency (MIM 222748) is an autosomal recessive disease
characterized by a large accumulation of dihydrouracil and
dihydrothymine in urine, blood and cerebrospinal ﬂuid. To date,
only 11 patients have been described with a complete DHP
deﬁciency, including ﬁve symptomless individuals who were
identiﬁed by a screening program for inborn errors of pyrimidine
degradation [7,23–31]. Therefore, the clinical, biochemical and
genetic spectrum of patients with a DHP deﬁciency is still largely
unknown. The clinical phenotype of ﬁve affected patients included
seizures, mental retardation, growth retardation and dysmorphic
features.
Here, we report on the clinical, biochemical and molecular
ﬁndings of 17 newly identiﬁed patients and 3 previously charac-
terised patients [23,31] with a complete DHP deﬁciency and the
functional and structural consequences of the mutations at the
protein level.
2. Materials and methods
2.1. Patients
The patients were collected in seven European countries and
Australia. Criteria to test for a metabolic disorder in general or
speciﬁcally for a disturbed purine/pyrimidine metabolism vary in the
various countries. General testing for a metabolic disorder is
considered indicated in patients suffering from developmental
delay, neurological manifestations (such as ataxia or dystonia),
enlarged liver and spleen or thickened gums, skeletal dysostosis and
in patients with prolonged signs and symptoms of the hematological,
immunological, ophthalmological and gastrointestinal systems. In this
way, 17 patients were identiﬁed in whom a dihydropyrimidinase
deﬁciency was likely. Subsequent analysis of family members of the
affected patients revealed another three probably affected persons.
Samples of all patients with a possible abnormality were forwarded to
the Laboratory for Genetic Metabolic Diseases in Amsterdam for
further analysis.
2.2. Analysis of pyrimidines in body ﬂuids
Concentrations of uracil, thymine, dihydrouracil, dihydrothymine,
N-carbamyl-β-alanine and N-carbamyl-β-aminoisobutyric acid in
urine, plasma and CSF were determined using reversed-phase HPLC
combined with electrospray tandem mass spectrometry [32].
2.3. PCR ampliﬁcation of coding exons
DNA was isolated from EDTA blood by standard procedures. PCR
ampliﬁcation of all nine coding exons and ﬂanking intronic regions
was carried out using the primer sets as described previously [31]. PCR
products were separated on 1.5% agarose gels, visualized with
ethidium bromide and used for direct sequencing.
2.3.1. Expression of DHP in E. coli
To obtain an expression plasmid containing wild-type human DHP
cDNA (pSE420-DHP), the EcoRI-BamHI insert of a plasmid comprising
the complete coding region of the human DHP gene was subcloned
into the pSE420 vector [33]. Mutations were introduced into the
human DHP sequence using the megaprimer technique and the
resulting mutant genes cloned into the pSE420 vector. Resulting
clones were sequenced completely to verify the presence of the
mutation and to exclude the presence of random mutations
introduced by PCR artifacts. Expression plasmids were introduced
into the E. coli strain BL21 and wild-type DHP and mutant DHPs were
expressed as described before [8]. Cells werewashedwith an isolation
buffer (35 mM potassium phosphate pH 7.4 and 2.5 mM MgCl2 and
resuspended in 300 μl of isolation buffer. The cell suspension was
641A.B.P. van Kuilenburg et al. / Biochimica et Biophysica Acta 1802 (2010) 639–648frozen for 16 h at−20 °C, thawed on ice and lysed by sonication. The
crude lysate was centrifuged at 18,000 g for 15 min and the resulting
supernatant was stored at −80 °C.
The activity of DHP was determined at 37 °C in a standard assay
mixture containing an aliquot of cell supernatant, 100 mM Tris–HCl
(pH 8.0), 1 mM dithiothreitol and 500 μM [6-14C]dihydrouracil with
subsequent separation of radiolabeled dihydrouracil from N-carba-
myl-β-alanine with reversed-phase HPLC [34].
2.4. Western blot analysis
Cell supernatants (10 μg) were fractionated on a 7.5% (w/v) SDS-
polyacrylamide gel and transferred to a nitrocellulose ﬁlter. Detection
of DHP proteins was performed using a polyclonal antibody against
rat DHP [8]. Antigen–antibody complexes were visualized using anti-
rabbit antibody conjugated to alkaline phosphatase.
2.5. Sequence analysis
Sequence analysis of genomic fragments ampliﬁed by PCR and
expression plasmids was carried out on an Applied Biosystems model
3730 automated DNA sequencer using the Big dye-terminator method
(Perkin Elmer Corp., Foster City, CA). DPYS sequence of patients was
compared to that observed in controls and the reference sequence of
DPYS (Ref Seq NM_001385.2; Ensembl ENST 00000351513).
2.6. Crystal structure analysis
The analysis of the crystal structure of human DHP (PDB accession
code: 2vr2) was performed using WinCoot [35,36]. The crystal
structures of slime mold, yeast and Sinorhizobium meliloti DHP, as
well as of homologous collapsin-response mediator proteins and
hydantoinases were used for comparative analyses (PDB accession
codes: 2ftw and 2fty [11], 3dc8 [37], 1kcx [21], 2gse [22], 1yny [16],
1k1d [18], 1nfg [20], 1gkp [17], 1gkr [19]). The ﬁgures showing the
point mutation sites and their environment of the human DHP proteinTable 1
Phenotype of 20 patients with DHP deﬁciency (−, none; +, mild; ++, severe).
Patienta Age
(years)
Gender Growth
retardation
Failure
to thrive
Feeding
problems
Microcephaly
1 (MA) 3.0 F − − + −
2.1 (TR) 4 M − − − −
2.2 (TR) 3 M − − − −
3 (TR) 0.7 M − + + −
4 (TR) 1.6 M − − + −
5 (TR) 0.6 F − + + −
6.1 (HT) 23 F − − − −
6.2 (HT) 17 F − − − −
6.3 (HT) 5 F − − − −
7 (TR) 14 F ++ − − −
8 (TR) 9 F − − − ++
9 (TR) 2 M − − + −
10 (IT) 5 F − − + −
11 (SE) 11 F + − − −
12 (GR) 5.9 F ++ ++ − ++
13 (DE) 11 F − − − −
14 (VE) 2.0 F − − − −
15 (LY) 7 F − − − −
16 (UK) 0.1 M ++ ++ ++ ++
17 (TR) 3.5 M − − − −
Total 20% (4/20) 20% (4/20) 35% (7/20) 15% (3/20)
a The nationality of the patient is given in parenthesis. 1Anal atresia, underdeveloped dist
chorea, progressive neuronal atrophy, MRI cortical atrophy [27,61]; 2MRI mild parieto-occipit
atrophy [28]; 4data from [24,25]; 5Tyrosinemia type II, asymptomatic at the age of 10; 6.1Prot
malabsorption with villous atrophy; 7Gall stones, hypermetropia; 8MRI porencephaly; 9Gas
defect, hypertelorism, ﬂat nasal bridge, short philtrum, thin upper lip vermillion, ﬁft
14Cardiomyopathy; 15Ataxia, cataract; 16In vitro fertilisation pregnancy, severe respiratorywere generated using the program PyMOL (DeLano, W.L. The PyMOL
Molecular Graphics System (2002), url: http://www.pymol.org).
3. Results
3.1. Clinical phenotype
Clinical features in the 20 DHP deﬁcient patients showed a
considerable variation in presentation (Table 1). Mental retardation,
hypotonia and seizures were observed in 63%, 45% and 30% of the
patients, respectively. Growth retardation, failure to thrive, micro-
cephaly and autism were observed less frequently. Forty-ﬁve percent
of the patients presented with gastrointestinal problems (feeding
problems, cyclic vomiting, gastroesophageal reﬂux, malabsorption
with villous atrophy). One patient suffered from a combined
deﬁciency of DHP and a tyrosinemia type II and another patient had
both DHP deﬁciency and congenital microvillous atrophy [28].
Phenotypic variability of DHP deﬁciency was demonstrated in two
families in which the index patient was clinically affected whereas the
same genotype did not lead to overt symptoms in siblings.
3.2. Biochemical phenotype
Urine and plasma samples of the patients showed strongly
elevated levels of dihydrouracil and dihydrothymine and moderately
elevated levels of uracil and thymine (Fig. 2). The dihydrouracil and
dihydrothymine concentrations were 16- to 135-fold and 15- to 197-
fold, respectively, higher compared to the mean concentration
observed in urine of controls. In plasma, the concentrations of
dihydrouracil and dihydrothymine were 5- to 25-fold and 7- to 29-
fold, respectively, higher compared to the mean concentration
observed in controls. Analysis of CSF also showed highly elevated
levels of dihydrouracil (20±6 μM, n=4; controls 2.2±0.9, n= 16)
and dihydrothymine (27±4 μM, n= 4; controls 0.8±0.2 μM,
n= 16). In DHP deﬁcient patients, a strong correlation existed
between urinary concentration of dihydrouracil and dihydrothymineMental
retardation
Seizures Hypotonia Autism Other Consanguinity
++ + + − 1 yes
− − − − 2 no
− − − −
+ − + − 3 yes
− + − − 4 yes
+ − + − 5 yes
+ + − − 6.1 no
− − − − no
− − − − no
+ − − − 7 yes
++ ++ + + 8 yes
+ − ++ − 9 yes
+ − − ++ 10 no
− − − − 11 no
++ ++ + − 12 no
+ − − − 13 no
− − − − 14 no
+ − + − 15 yes
? + + − 16 yes
+ − + + 17 no
63% (12/19) 30% (6/20) 45% (9/20) 15% (3/20)
al phalanges of 3rd ﬁngers, coarse face, broad nasal bridge, prominent and simple ears,
al whitematter loss, severe delay in speech development [31]; 3Congenital microvillous
ein S deﬁciency, cerebral thrombophlebitis leading to hemiparesia, antigliadin negative
troesophageal reﬂux, 10Mild facial coarsening; 11Cyclic vomiting; 12Ventricular septum
h ﬁnger clinodactyly; 13Macrocephaly, obesity, Paroxysmal theta waves on EEG;
problems of infancy, demise at 4 weeks of age; 17hyperactive behavior.
Fig. 2. Concentrations of dihydropyrimidines and pyrimidine bases in DHP patients and controls. Panel A shows the urinary levels of dihydrouracil (DHU) and dihydrothymine (DHT)
and panel B shows the concentrations of the pyrimidine bases in urine. The plasma levels of the dihydropyrimidines and the pyrimidine bases are shown in panels C and D,
respectively. The top, bottom and line through the middle of a box correspond to the 75th percentile, 25th percentile and 50th percentile, respectively. The whiskers on the bottom
extend from the 2.5th percentile and top 97.5th percentile. The circles represent outliers.
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dihydrouracil and dihydrothymine concentration in plasma
(R2=0.72, P= 0.028). Thus, dihydropyrimidinuria in these patients
strongly suggested DHP deﬁciency.
3.3. Genotype
DPYS analysis in the 17 hitherto uncharacterized patients showed
one previously described missense mutation (L7V) and 13 novel
mutations, including eight missense mutations, two nonsense muta-
tions, two deletions and one splice-site mutation (Table 2). Homo-
zygosity for one of the identiﬁed mutations was observed in 11
patients. The mutations c.1078TNC, c.1027ANG and c.1092 + 3delG
were each present in two unrelated patients and c.1137CNA was
identiﬁed in four unrelated patients. Fig. 3 shows the distribution of
DPYS mutations over the exons. In particular exons 5–8, representing
41% of the coding sequence, harbour 71% of themutations. An analysis
for the presence of the 14 mutations in 90 controls did not identify
individuals either heterozygous or homozygous for one of these
mutations.3.4. Functional analysis of mutant DHP enzymes
To investigate the effect of the nine missense and two nonsense
mutations on the activity of DHP, the mutations were introduced
into a pSE420-DHP vector by site-directed mutagenesis and ex-
pressed in E. coli. No endogenous DHP activity (b0.3 nmol/mg/h)
could be detected in the E.coli strain used for the expression of
the constructs. Introduction of wild-type DHP construct increased
DHP activity more than 300-fold above the background level.
Expression of DHP constructs containing the mutations p.W360R,
p.V364M, p.D81G, p.L7V, p.M70T, p.L337P and p.R465X yielded
no detectable DHP activity (b0.2%) (Fig. 4). Expression of the
mutant DHP constructs containing the p.S379R and p.R490C and
p.R475X mutation yielded a residual activity of 0.2–0.9%. Signiﬁcant
residual DHP activities were detected for mutant DHP enzymes
containing the p.R302Q (3.9% activity) and p.T343A mutation (49%
activity).
To exclude the possibility that the lack of DHP activity was the
result of an inability to produce the mutant protein in E. coli, the
expression levels were analysed by immunoblotting. Fig. 4 shows that
Table 2
Results of mutation analysis in 20 patients with DHP deﬁciency.
Patient Genotype Effect Location
1a c.[1078TNC]+[1078TNC] p.[W360R]+[W360R] Ex 6
2.1b c.[1078TNC]+[1235GNT] p.[W360R]+[R412M] Ex 6, Ex 7
2.2b c.[1078TNC]+[1235GNT] p.[W360R]+[R412M]
3 c.[905GNA]+[905GNA] p.[R302Q]+[R302Q] Ex 5
4 c.[1137CNA]+[1137CNA] p.[S379R]+[S379R] Ex 7
5 c.[476delA]+[476delA] p.[K159RfsX12]+[K159RfsX12] Ex 3
6.1 c.[19CNG]+[209TNC] p.[L7V]+[M70T] Ex 1
6.2 c.[19CNG]+[209TNC] p.[L7V]+[M70T] Ex 1
6.3 c.[19CNG]+[209TNC] p.[L7V]+[M70T] Ex 1
7 c.[1468CNT]+[1468CNT] p.[R490C]+[R490C] Ex 9
8 c.[1423CNT]+[1423CNT] p.[R475X]+[R475X] Ex 8
9 c.[1092+3delG]+[1092+3delG] unknown IVS6
10 c.[1092+3delG]+[1092+3delG] unknown IVS6
11 c.[1010TNC]+[1010TNC] p.[L337P]+[L337P] Ex 6
12 c.[1090GNA]+[1137CNA] p.[V364M]+[S379R] Ex 6, Ex 7
13 c.[242ANG]+[1027ANG] p.[D81G]+[T343A] Ex 1, Ex 6
14 c.[1027ANG]+[1393CNT] p.[T343A]+[R465X] Ex 6, Ex 8
15 c.[1137CNA]+[1137CNA] p.[S379R]+[S379R] Ex 7
16 c.[1254_1255delTC]+[1254_1255delTC] p.[His419SerfsX5]+[His419SerfsX5] Ex 8
17 c.[1137CNA]+[1137CNA] p.[S379R]+[S379R] Ex 7
a Data obtained from [23].
b Data obtained from [31].
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wild-type protein. Only expression levels of DHP enzymes containing
the mutation p.S379R, p.W360R and p.L7V were lower than that
observed for the wild-type DHP enzyme. Expression constructs
containing the two nonsense mutations p.R465X and p.R475X yielded
shortened DHP proteins. Thus, the lack of DHP activity of mutant DHP
enzymes in E. coli is not due to rapid degradation of the various
mutant DHP proteins in the E. coli lysates.
3.5. Structural effects of DHP mutations
Fig. 5A depicts the location of all presently reported pointmutation
sites within the subunit of human DHP. None of the affected residues
is located within the active site, excluding direct interference with
substrate binding. However, some of the residues are engaged in
interactions that may be important for maintaining structural
integrity of the active site or of subunit interfaces in the DHP tetramer
(Fig. 5B).
R302 is almost strictly conserved in DHP homologues. Its side
chain forms hydrogen bonds and/or charged interactions with E218,
E226 and R220, thus connecting the loop leading to the seventh
barrel-helix with several secondary structure elements that are
strongly engaged in subunit contacts (Fig. 6A). The R302Q mutation
abolishes most hydrogen bonding possibilities and does not provide
any charge compensation for the E218 and E226 side chains. The likely
consequence is increased local ﬂexibility with potentially disturbed
subunit interactions.Fig. 3. Genomic organisation and mutation analysis of DPYS. DPYS consists of 10 exons en
identiﬁed in DHP deﬁcient patients are indicated, numbers correspond to the cDNA positioA similar consequence is expected for the mutation of V364,
belonging to a helix-loop-helixmotif that interacts with residues from
another subunit. In DHPs homologs, its environment shows higher
sequence variance than residue 364 itself but the hydrophobic
character of both is always retained. The V364M mutation exchanges
a smaller by a larger hydrophobic side chain, resulting in steric clashes
with residues in its proximity such as W360 and F374 (Fig. 6B). Some
of these clashes may be prevented by other conformations of the
methionine, but readjustments of nearby side chains to optimize their
packing are required in either case. Previously, another mutation with
activity-abolishing effects has been identiﬁed and localized in the
same area (W360R) [31], suggesting that it is very sensitive to
structural disturbances.
The side chain of R490 anchors the C-terminal tail of one subunit to
the surface of another via van der Waals interactions and hydrogen
bonds to E215, Y284 and N286 (Fig. 6C). A mutation to cysteine
(R490C) is expected to increase the ﬂexibility of the C-terminal tails,
leading to disturbances in tetramer association. This is in line with the
observation that in microbial hydantoinases, C-terminal regions are
not essential for catalysis but affect oligomeric structure [38] and can
explain the very low residual activity of truncated human DHP protein
(p.475X), lacking the last 45 amino acids.
L7 belongs to the β-sandwich domain and is distant from the
active site and subunit interfaces. Its side chain involves in
hydrophobic interactions with nearby residues (Fig. 6D). The apolar
character of the interactions is conserved in most structural homo-
logues. Exchange of L7 to valine shortens the side chain but retains itscoding an open reading frame of 1560 bp (depicted in gray). The various mutations
n.
Fig. 4. DHP activity and immunoblot analysis of wild-type andmutant DHPs expressed in E. coli. The results represent the mean of three to six independent measurements, the error
bar represents 1 SD.
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obvious. Possible, loss of the methyl group weakens hydrophobic
interactions by leaving a hole in the otherwise tightly packed cluster
of apolar side chains. It is uncertain whether the resulting increased
local ﬂexibility is sufﬁcient to cause global protein instability or to
inﬂuence folding dynamics.
S379 is located in the tightly packed interface between the
catalytic and the β-sandwich domain (Figs. 5A, 6E) opposite a strictly
conserved glycine (G62) that connects the third strand of a β-
sandwich sheet with the ﬁrst strand of the (β/α)8-barrel. The latter
precedes the HxH motif important for binding of the di-zinc centre.
In homologs of human DHP the serine is either conserved or replaced
by cysteine or alanine (Table 3), indicating there is no space for a
larger side chain. Thus, the S379R mutation might cause enzyme
misfolding.
M70T, D81G, L337P, and T343A have indirect effects on zinc ion or
substrate binding by perturbing the ﬁne-tuned geometry within and
near the active site. M70 directly follows the zinc-binding HxH motif
and engages in hydrophobic interactions with e.g. I98, V352, F83, T68
and T87 (Fig. 6F). The nearby D100 forms hydrogen bonds with M70
and T68, thus ﬁxating the position of both neighbours of zinc-ligand
H69. The M70T mutation is predicted to have one or several of the
following consequences, each affecting enzyme structure and stabil-
ity: 1. inability of the shorter, polar side chain of threonine to form
favourable hydrophobic contacts with its environment; 2. steric
clashes with F83 and other nearby amino acids; 3. disturbance of the
native interactions of D100 due to formation of a hydrogen bond with
T70.
Mutation of D81 to glycine would abolish both hydrogen bonds
involving the aspartate side chain, i.e., those to Q421 and T329 (Fig.
6G). The aspartate is conserved in most homologues of human DHP
(Table 3), while in A. aurescens hydantoinase the carboxyl group of anearby aspartate is placed at a spatially equivalent position, forming
the same interactions. This underlines the crucial role of D81 in
interconnecting domains as well as secondary structure elements
carrying zinc-ligating residues.
The mutation sites L337 and T343 are spatially close to each other
in one of the long loops protruding from the top of the barrel that
shapes the entrance to the active site (Fig. 6G). This loop contains
helical elements and leads into a conserved sequence motif,
345IPNG348 in human DHP. N347 of this motif is a substrate binding
residue, interacting with atom N1 of the dihydropyrimidine and the
following glycine is involved in positioning the substrate binding
residue G298. L337 and T343 are located at the outmost periphery of
the protein in two consecutive 310-helical turns. Replacement of L337
by other residues than proline most likely has modest effects; the side
chain is oriented towards the bulk solvent and only involved in weak
hydrophobic interactions. Proline, however, tends to break or kink
helices due to its conformational rigidity and inability to donate an
amide hydrogen bond. Partial unwinding of its helical components
may cause considerable increase in ﬂexibility or disorder of the long
loop segment participating in constructing the substrate binding site.
T343 seems to play a role in the structural ﬁxation of the tip of this
loop. Mutation to alanine eliminates the hydrogen bond to D341 and
weakens hydrophobic interactions with F342 and residues extending
from the closest barrel-helix. However, the hydrogen bond formed
between D341 and K344 may provide sufﬁcient structural stability to
this region allowing tolerance the T343A exchange. This would
explain the signiﬁcant residual activity of the mutant.
4. Discussion
DHP deﬁciency is an inborn error of the pyrimidine degradation
pathway, affecting the ring opening of both dihydrouracil and
Fig. 5. Structure of human DHP and location of point mutation sites. (A) Stereoview of the human DHP subunit in cartoon representation, with secondary structure elements depicted
in different shades of green and zinc ions of the di-metal centre as black spheres. Location of the point mutation sites reported herein is indicated by space-ﬁll representation and
labelling of the corresponding residues. (B) Stereoview of the human DHP homotetramer in cartoon representation. One subunit is shown as depicted in panel A, including mutation
sites, while the other subunits are depicted in orange, red and blue. Zinc ions are shown as black spheres.
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strongly elevated levels of dihydropyrimidines in urine, plasma and
CSF. The most frequently observed clinical features in the present
study were mental retardation, hypotonia and seizures which is
comparable to that observed for patients with a DPD deﬁciency [39–
41]. An unexpected ﬁnding was the high frequency of gastrointestinal
problems in DHP deﬁcient patients. The identiﬁcation of individuals
with complete DHP deﬁciencywithout any clinical manifestations and
the marked intrafamilial variability in phenotype, indicate that
additional (epi)genetic and environmental factors are likely to be
involved.
The pathogenesis underlying the various clinical manifestations
remains as yet unknown. Biochemically, patients with a deﬁciency in
one of the three enzymes of the pyrimidine degradation pathway
show moderately decreased levels of β-alanine and strongly de-
creased levels of β-aminoisobutyric acid [42–44]. β-Alanine is a
structural homologue of γ-aminobutyric acid and glycine, which are
the major inhibitory neurotransmitters in the central nervous system.
β-alanine itself has been suggested to be involved in synaptic
transmission and has been shown to regulate dopamine levels[39,45]. In addition, β-alanine is the rate-limiting substrate for the
synthesis of carnosine. Oral administration of β-alanine increases the
carnosine content in muscles and delays the onset of neuromuscular
fatigue while improving endurance performance and lean body mass
[46–49]. β-Aminoisobutyric acid is a partial agonist of the glycine
receptor [50]. Recently, it was demonstrated that β-aminoisobutyric
acid is able to increase the excretion of leptin and stimulate fatty acid
oxidation [51]. Leptin itself has been shown to have neuroprotective,
cognitive and anticonvulsant effects [52–54]. Thus, it is conceivable
that the altered homeostasis of β-aminoisobutyric acid in patients
with DHP deﬁciency might affect leptin levels and fatty acid oxidation
and contribute to the development of mental retardation and
hypotonia in the patients.
Mammalian DHP uses not only 5,6-dihydrouracil and 5,6-dihy-
drothymine as substrates but also catalyses the hydrolysis of a variety
of other compounds [13,55–58]. The broad substrate speciﬁcity of
DHP could implicate that DHP is involved in detoxiﬁcation of
endogenous compounds and xenobiotics. In addition, DHP is highly
homologous to the non-catalytically active dihydropyrimidinase-like
proteins which play an important role in neuronal development
Fig. 6. Mutation sites and their environment in human DHP crystal structure. The cartoon representation of the human DHP backbone is depicted in green. Otherwise not further
discussed side chains are shown in green as thin sticks. Zinc ions of the di-metal centre are depicted as black spheres. Residues are labelled and shownwith thicker sticks and oxygen
atoms in red, nitrogen atoms in blue and sulphur atoms in dark yellow. For residues in wild-type human DHP, carbon atoms are coloured yellow. Carbon atoms in cyan mark side
chains introduced by the point mutations. Identity of various mutation sites is indicated below each ﬁgure. In ﬁgures (A)–(F) the sites are labelled by asterisks. Hydrogen bonds are
indicated by dotted black lines. The (energetically preferred) side chain conformation causing the least clashes andmost optimal interactions with surrounding residues was chosen.
(A) Distant view of the R302Q mutation site showing its location close to an oligomerization interface within the DHP tetramer. For clarity, only the side chain at the mutation site
and of its interaction partners are depicted. One subunit is shown in green, another in red. (B) Close-up view of the V364Mmutation site. The C-terminal tail of another subunit that
interacts with the loop-region following themutation site is shown in orange. (C) Close up view of the R490Cmutation site. Stick representation is only used for the residues of the C-
terminal tail of one subunit (in green), the residue at the mutation site (yellow carbon atoms for the arginine of the wild-type DHP and cyan carbon atoms for the cysteine of the
mutant), and for interacting residues of a neighbouring subunit (orange carbon atoms). The subunit harbouring the depicted R490 is shown in green, the others in red, orange and
blue. (E) Close-up view of the L7V mutation site. The yellow surface represents the van der Waals sphere of the mutated residue, while corresponding spheres of neighbouring
residues are depicted by yellow and blue dots. (E)–(F) Close-up views of the S379R and M70T mutation sites. (G) Stereo view of the D81G, L337P and T343A mutation sites. For
clarity, stick representation is only used for residues mentioned in the text. Residues belonging to the conserved sequence motif involved in substrate binding and the zinc-ligating
H67 and H69 are shown with orange carbon atoms.
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might have similar additional functions as well.
Mutation analysis of DPYS showed 14 mutations, including nine
missense mutations, two nonsense mutations, two deletions and one
splice-site mutation. Systematic analysis of the sequences present in
the vicinity of the splice junctions has led to consensus sequences for
both the splice acceptor and splice donor sites [59]. A scoring system
developed by Shapiro and Senapathy showed that most naturally
occurring splice acceptor and splice donor sites yielded scores above
0.70. Analysis of the consensus sequence of the authentic splice donor
site of exon 6 of DPYS showed that the c.1092 + 3delG mutation
reduces the consensus value from 0.73 (wild-type) to 0.61 (mutant).
Heterologous expression of 11 mutant enzymes in E. coli showed thatall but 2 missense mutations yielded mutant DHP proteins without
signiﬁcant activity (b1%). Only DHP containing the mutations p.
R302Q and p.T343A possessed 3.9% and 49% residual enzymatic
activity, respectively. This observation is in line with the fact that the
two patients who were compound heterozygous for the p.T343A
mutation presented with relatively low urinary concentrations of the
dihydropyrimidines.
The crystal structure of human DHP showed that the native
enzyme is composed of four identical subunits containing two zinc
ions [12]. Each subunit consists of two domains, a larger (β/α)8-barrel
domain that binds the catalytic di-zinc centre, and a smaller domain
with a β-sandwich fold. The core elements of the latter are a seven-
stranded and a four-stranded mixed β-sheet (Fig. 5A). Both domains
Table 3
Sequence conservation amongst DHPs and homologs at selected positions.
Proteina Mutation sites in human DHPase and corresponding residues
HsDHPase L7 M70 D81 R302 L337 T343 V364 S379 R490
DdDHPase I F D R M T V S V
SkDHPase L V D R R R Y C -
DmDHPase⁎ V M D R L T V S E
AtDHPase⁎ I L D R L R V S P
MmDHPase⁎ L M D R L T V S R
RnDHPase⁎ L M D R L T V S R
SmDHPase T L D R F T V S R
MmCRMP-1 L L D S V T V S R
HsCRMP-2 L F D S V T V S R
B9DHyd K L D R L T V S -
BsDHyd K L D R L T V S -
BpDHyd I V D R R R V A -
TsDHyd L I D R L T V S -
AaLHyd V I G R - - V C -
Residues corresponding to the mutation sites in human DHP were identiﬁed using
structure-based sequence alignments for all homologs of known structure. A hyphen
indicates the absence of a corresponding residue, either because of a shorter protein
sequence or because of signiﬁcant structural deviations from the HsDHP. Bold letters
indicate sequence conservation to human DHP. An asterisk marks enzymes for which
no 3D structural data are available.
a Abbreviations correspond to the following: Hs, Homo sapiens; Dd, Dictyostelium
discoideum; Sk, Saccharomyces kluyveri; Dm, Drosophila melanogaster; At, Arabidopsis
thaliana; Mm, Mus musculus; Rn, Rattus norvegicus; Sm, Sinorhizobium meliloti
CECT4114; B9, Bacillus sp. AR9; Bs, Bacillus stearothermophilus; Bp, Burkholderia
pickettii; Ts, Thermus sp.; Aa, Arthobacter aurescens; DHyd, D-stereospeciﬁc
hydantoinase; LHyd, L-stereospeciﬁc hydantoinases; CRMP, (non-enzymatic)
collapsin-response mediator protein.
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relevant homotetramers (Fig. 5B). Analysis of the environment of
the point mutation sites within the crystal structure of human DHP
allowed us to predict the effects of amino acid exchanges on structure
and function of the enzyme. The point mutations R490C, R302Q and
V364M prevent or disturb oligomerization to the physiologically
relevant homotetramer. In contrast, M70T, D81G, L337P and T343A
affect regions near the di-zinc centre and the substrate binding site
inﬂuencing active site geometry and metal-binding. S379R impairs
packing of the catalytic and β-sandwich domain against each other
which might cause protein misfolding. Only the potential effect of the
L7V exchange was less obvious, but may be based on structural
destabilization of the hydrophobic core of the β-sandwich domain.
Recently, it has been shown that patients with a partial DHP
deﬁciency are prone to the development of severe toxicity after the
administration of 5-ﬂuorouracil [7–10]. The present ﬁnding that
individuals with very low DHP levels can be symptomless urges for
careful analysis of cancer patients before 5FU administration. In
addition, the ﬁnding of four mutations in multiple DHP patients of
different nationalities may indicate that a DHP deﬁciencymight be not
as rare as generally considered. The prevalence of a DHP deﬁciency in
Japan has been estimated to be 1 in 10,000 which is comparable to the
estimated frequency of patients with a DPD deﬁciency in the
Netherlands [7,60]. The present results should facilitate identiﬁcation
of further individuals with decreased DHP activity.
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